VivoSeq
Oncology

HR+/HER2- Breast Cancer

6

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

HR+/HER2- Breast Cancer is an early-stage landscape with 6 programs across 5 companies. The most active players are Novartis, BeiGene, Eli Lilly. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

15/100

Mech. Concentration

20/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

2 programs

Phase 3BeiGene logo

BeiGene

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3B

BeOne Medicines

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Not yet recruiting1 · 33%

Clinical Trials

Trial Activity

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
Recruiting·BBeOne Medicines·Phase 3·NCT07492641·1,056 enrolled
An Exploratory Study to Evaluate the Efficacy and Safety of Kumorixilib Combined With Capecitabine and Letrozole as Neoadjuvant Therapy for HR-Positive, HER2-Negative Breast Cancer
Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07691333·35 enrolled
Real-world Evidence Non-Interventional proSpective Study of kisqaLi (Ribociclib) Effectiveness and safEty in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia
Recruiting·Novartis logoNovartis·N/A·NCT06797531·177 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)